Bio-Techne's (TECH) fiscal Q4 organic revenue growth of 3% is consistent with the progressive improvement story reflected in management's expectation of fiscal 2027 being a roughly 6% sales growth ...

Aug 12 (Reuters) - Bio-Techne beat Wall Street estimates for fourth-quarter revenue on Wednesday helped by growth in its research and diagnostics businesses. Here are some details: • Bio-Techne is in ...

Bio-Techne's Q4 revenues beat estimates as Diagnostics and Spatial Biology deliver strong organic growth, while its Merck deal remains in focus.

Life sciences company Bio-Techne (NASDAQ:TECH) reported Q2 CY2026 results , with sales up 1.3% year on year to $321.2 million. Its non-GAAP profit of $0.52 per share was in line with analysts’ ...

Detailed price information for Bio-Techne Corp (TECH-Q) from The Globe and Mail including charting and trades.

"Bio-Techne ended fiscal 2026 with improved performance and solid execution across the business, reflecting the value our differentiated solutions bring across biopharma, research ...

An integrated assay using proprietary RNAscope™ and miRNAscope™ technologies to measure the biodistribution and function of novel gene therapies and endogenous regulatory RNAs. Small regulatory RNAs, ...

For more information on Bio-Techne and its brands, please visit or follow the company on social media at LinkedIn , X , or YouTube . Forward Looking Statements: Our press releases may contain forward ...

Develops and manufactures life science reagents, analytical instruments, and diagnostic products, including proteins, antibodies, assays, and molecular diagnostic kits Generates revenue through the ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.